SCHEMBL3535449

SCHEMBL3535449

CC(C)(Cc1cc2nc(Cl)ccc2n1S(=O)(=O)c1ccccc1)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPARG P37231 8/20 0.56
PPARA Q07869 6/20 0.56
PPARD Q03181 4/20 0.45
ALDH1A1 P00352 3/20 0.42
HPGD P15428 2/20 0.42
HTT P42858 2/20 0.42
HSD17B10 Q99714 2/20 0.42
ALDH3A1 P30838 2/20 0.42
KDM4E B2RXH2 1/20 0.42
TSHR P16473 1/20 0.42
TBXA2R P21731 1/20 0.39
NOD1 Q9Y239 2/20 0.38
CXCL8 P10145 1/20 0.38
LMNA P02545 2/20 0.37
GAA P10253 1/20 0.37
ALOX5AP P20292 3/20 0.37
MAPT P10636 1/20 0.36
HTR6 P50406 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3530708 0.89 PPARG (0.71) PPARGPPARAPPARDALDH1A1HPGD
SCHEMBL3528148 0.84 PPARG (0.48) PPARGPPARAPPARDALDH1A1HPGD
SCHEMBL7213488 0.83 PPARG (0.48) PPARGPPARAPPARDALDH1A1HPGD
SCHEMBL16235830 0.81 PPARG (0.46) PPARGPPARAPPARDALDH1A1HPGD
SCHEMBL3535429 0.81 PPARG (0.68) PPARGPPARAPPARD
SCHEMBL21064305 0.80 PPARG (0.47) PPARGPPARAPPARDALDH1A1HPGD
SCHEMBL7214465 0.80 PPARG (0.46) PPARGPPARAPPARDALDH1A1HPGD
SCHEMBL27732238 0.80 PPARG (0.67) PPARGPPARAPPARD
SCHEMBL23436432 0.80 PPARG (0.43) PPARGPPARAPPARDALDH1A1HPGD
SCHEMBL3532156 0.79 PPARG (0.69) PPARGPPARAPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7728002-B2 Use of pyrrolopyridine compounds for activating PPAR receptors and treatment of conditions involving such receptors LABORATOIRES FOURNIER S.A. (FR) 2010-06-01 US disclosed
US-20090239856-A1 Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors LABORATOIRES FOURNIER S.A. (FR) 2009-09-24 US disclosed
US-7557122-B2 Pyrrolopyridine compounds, method of making them and uses thereof LABORATOIRES FOURNIER S.A. (FR) 2009-07-07 US disclosed
US-20080200495-A1 Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239856-A1 Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors PPARD, PPARA, PPARG PPARG 3/4885PPARA 2/4885PPARD 1/4885
US-20080200495-A1 Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof LIPG, PCSK9, PNLIP PPARG 335/4885PPARA 168/4885PPARD 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.